Suppr超能文献

法洛四联症患者止血功能和肝损伤的横断面评估。

Cross-sectional assessment of haemostatic profile and hepatic dysfunction in Fontan patients.

机构信息

Cardiology, University Medical Centre Amsterdam, Amsterdam, Netherlands

Heamatology Research, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia.

出版信息

Open Heart. 2021 May;8(1). doi: 10.1136/openhrt-2020-001460.

Abstract

BACKGROUND

Fontan-associated liver disease is accompanied by a hypercoagulable state. While hepatic dysfunction in Fontan patients is common, its relationship with haemostatic changes and clinical outcomes in this patient population remains unclear.

OBJECTIVE

To correlate liver dysfunction and haemostatic profiles with clinical outcomes in the Fontan population.

PATIENTS/METHODS: Patients were enrolled in a multicentre, cross-sectional study in Australia and New Zealand. Hepatic structure and function were assessed using serum-based calculations (Fibrotest and model for end-stage liver disease excluding international normalised ratio scores). Haemostatic profiles were assessed by Thrombin Generation. Platelet function was assessed via Platelet Factor 4 (PF4) and P-selectin (P-SEL). Clinical outcomes were obtained from the Australian and New Zealand Fontan Registry.

RESULTS

Seventy-three patients participated in the study (mean age 18.9±8.5 years with a mean of 13.5±6.9 years post-Fontan). The Endogenous Thrombin Potential (ETP) for patients who suffered thrombotic events (TE) (1366.4±66.2 nM/min) was higher compared with patients with major bleeding events (1011.1±138.4 nM/min) (p=0.03). Except for a negative correlation between Fibrotest-score and PF4 (p=0.045), PF4 and P-SEL concentrations did not correlate with markers of hepatic dysfunction or structural abnormality.

CONCLUSIONS

Increased ETP is associated with TE during clinical follow-up after Fontan. This study reinforces that hepatic dysfunction may contribute to the derangement of coagulation factors, impacting the individual risk of haemostatic complications for the Fontan population.

摘要

背景

Fontan 相关肝疾病伴有高凝状态。虽然 Fontan 患者的肝功能障碍很常见,但在该患者人群中,其与止血变化和临床结局的关系尚不清楚。

目的

将肝功能障碍和止血谱与 Fontan 人群的临床结局相关联。

患者/方法:患者在澳大利亚和新西兰的多中心横断面研究中入选。使用基于血清的计算方法(Fibrotest 和排除国际标准化比值评分的终末期肝脏疾病模型)评估肝结构和功能。通过凝血酶生成评估止血谱。通过血小板因子 4(PF4)和 P-选择素(P-SEL)评估血小板功能。临床结局来自澳大利亚和新西兰 Fontan 登记处获得。

结果

73 名患者参与了这项研究(平均年龄 18.9±8.5 岁,Fontan 术后平均 13.5±6.9 年)。发生血栓形成事件(TE)的患者的内源性凝血酶潜能(ETP)(1366.4±66.2 nM/min)高于发生大出血事件(1011.1±138.4 nM/min)的患者(p=0.03)。除了 Fibrotest 评分与 PF4 呈负相关(p=0.045)外,PF4 和 P-SEL 浓度与肝功能障碍或结构异常的标志物均无相关性。

结论

在 Fontan 后临床随访期间,增加的 ETP 与 TE 相关。本研究进一步证实,肝功能障碍可能导致凝血因子紊乱,影响 Fontan 人群发生止血并发症的个体风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f09c/8112412/093cba1f8bec/openhrt-2020-001460f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验